DMAC vs ICE · $157.4M cap vs P/E 37, rev $12.64B
DiaMedica Therapeutics Inc (DMAC) versus Intercontinental Exchange Inc (ICE) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Intercontinental Exchange Inc (ICE) is a financial data & stock exchanges company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported ICE revenue for 2025-12-31 was $12.64B. Net income was $3.31B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. ICE currently screens at market cap $103.55B and trailing P/E 37.3.
DMAC currently screens at market cap $157.4M. ICE currently screens at market cap $103.55B and trailing P/E 37.3.
Not investment advice. Open the DMAC and ICE stock pages for the full models.
Not investment advice.